Skip to content
Screener

Beam Therapeutics BEAM External General And Administrative Expenses — General And Administrative Expense

Other segment segments

Employee Related Expenses
$11.95M+14.5%

Similar metrics at other companies

TRA
TRAXExternal Expenses — General And Administrative Expense
$8.72M+127%
AnaptysBio, Inc. logo
ANABExternal Expenses — General And Administrative Expense
$12.12M+119%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — General And Administrative Expense
$6.33M+19.9%
AnaptysBio, Inc. logo
ANABInternal Expenses — General And Administrative Expense
$14.08M+63.9%
Solid Biosciences Inc. logo
SLDBInternal General And Administrative Expense — General And Administrative Expense
$4.73M+40.9%
TRA
TRAXInternal Expense — General And Administrative Expense
$10.14M+69.9%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.81B+52.0%
Enterprise value$2.78B+61.1%
P/S17.2×-13.6×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
External research and development expenses*30,07734,421
Employee related expenses*32,86729,242
General and administrative expenses
External general and administrative expenses*13,3665,373
Employee related expenses*11,95110,441
Facility and information technology related expenses*14,43814,383
Depreciation and amortization5,6055,528
Stock-based compensation19,04426,682

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's external general and administrative expenses — general and administrative expense?
Beam Therapeutics (BEAM) reported external general and administrative expenses — general and administrative expense of $13.37M in Q1 2026.
How has Beam Therapeutics's external general and administrative expenses — general and administrative expense changed year-over-year?
Beam Therapeutics's external general and administrative expenses — general and administrative expense increased by 148.8% year-over-year, from $5.37M to $13.37M.
What is the long-term trend for Beam Therapeutics's external general and administrative expenses — general and administrative expense?
Over 3 years (2022 to 2025), Beam Therapeutics's external general and administrative expenses — general and administrative expense has grown at a 3.0% compound annual growth rate (CAGR), from $25.89M to $28.32M.
What does external general and administrative expenses — general and administrative expense mean?
This metric represents the total operating costs incurred by the company to support its corporate infrastructure, including executive management, legal, finance, and human resources functions. It captures the overhead required to sustain business operations outside of direct research and development activities. Monitoring this expense helps investors evaluate the company's operational efficiency and the scalability of its administrative support structure as it advances its genetic medicine pipeline.

Ask your AI about Beam Therapeutics's external general and administrative expenses — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude